Narita Keisuke, Hoshide Satoshi, Kario Kazuomi
a Division of Cardiovascular Medicine, Department of Medicine , Jichi Medical University School of Medicine , Tochigi , Japan.
b Department of Cardiology , Karatsu Red Cross Hospital , Saga , Japan.
Expert Rev Cardiovasc Ther. 2018 Dec;16(12):889-895. doi: 10.1080/14779072.2018.1538784. Epub 2018 Oct 25.
Randomized controlled trials and meta-analyses have established the benefits of blood pressure (BP) lowering. The 2017 American Heart Association/American College of Cardiology (AHA/ACC) guidelines for the management of hypertension established 130/80 mmHg as the threshold for the diagnosis- and treatment-target BP level. Area covered: The global trends are thought to be heading toward intensive BP-lowering management. In this paper, authors summarize the evidence on lowering the BP target in hypertensive patients with a focus on the 2017 AHA/ACC guidelines. Expert commentary: According to the results of clinical research, meta-analyses and the 2017 AHA/ACC guidelines, the target systolic BP may change from less than 140/80 mmHg to 130/80 mmHg in any other international hypertension guidelines. However, this direction of intensive BP control is still controversial.
随机对照试验和荟萃分析已经证实了降低血压（BP）的益处。2017年美国心脏协会/美国心脏病学会（AHA/ACC）高血压管理指南将130/80 mmHg确立为诊断和治疗目标血压水平的阈值。涵盖领域：全球趋势被认为正朝着强化血压管理的方向发展。在本文中，作者以2017年AHA/ACC指南为重点，总结了关于降低高血压患者血压目标的证据。专家评论：根据临床研究、荟萃分析的结果以及2017年AHA/ACC指南，在任何其他国际高血压指南中，收缩压目标可能会从低于140/80 mmHg变为130/80 mmHg。然而，这种强化血压控制的方向仍存在争议。
